BioVie Highlights Encouraging NE3107 Data In Parkinson’s, Alzheimer’s Trials
BioVie Inc (NASDAQ:BIVI) announced results from two Phase 2 trials assessing NE3107’s potential in Parkinson’s Disease (PD) and Alzheimer’s Disease (AD).…
How Is The Market Feeling About BioVie?
BioVie's (NASDAQ:BIVI) short percent of float has fallen 5.22% since its last report. The company recently reported that it has 167 thousand shares sold short, which is 2.36% of all regular shares that are available for trading.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 108 stocks hit new 52-week highs.
BioVie Announces Phase 2 Trial Assessing NE3107’s Pro-motoric Activity In Parkinson’s Disease Is Fully Enrolled
BioVie Inc., (NASDAQ:BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and
Alphabet To $136? Plus This Analyst Slashes PT On United Natural Foods
Truist Securities cut the price target on Alphabet Inc. (NASDAQ: GOOGL) from $145 to $136. Truist Securities analyst Youssef Squali maintained a Buy rating on the stock. Alphabet shares rose 2.5% to $99.90 on Wednesday.
Benzinga Pro’s Top 5 Stocks To Watch For Wednesday, Sept. 28, 2022: AAPL, KMX, GNRC, DOCU, BIVI
Apple (AAPL) - Shares traded down about 2.5% Tuesday evening following a report the company pulled back its iPhone 14 production ramp up, citing underwhelming demand. Several notable analysts, including Loup
How Is The Market Feeling About BioVie?
BioVie's (NASDAQ:BIVI) short percent of float has fallen 67.41% since its last report. The company recently reported that it has 54 thousand shares sold short, which is 0.44% of all regular shares that are available for trading.
